Decibel Therapeutics Inc

DBTX | $4.91 -0.81% -0.2% 0

(0.0% 1d) (0.0% 1m) (58.4% 1y) (-0.8% 2d) (-1.4% 3d) (0.0% 7d) (283.12% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 123,373,251
https://www.decibeltx.com
Sec Filling | Patents | 40 employees

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

urea ceiling treatment gene therapies t-cell

add to watch list Paper trade email alert is off